芬妥木单抗(Figitumumab) - 药物靶点：IGF-1R_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-IGF-1R monoclonal antibody(Pfizer)、Figitumumab (USAN)、CP-751871

靶点

IGF-1R

作用机制

IGF-1R拮抗剂(胰岛素样生长因子-I受体拮抗剂)

治疗领域

肿瘤呼吸系统疾病消化系统疾病+ [6]

在研适应症-

非在研适应症

腺鳞癌晚期乳腺癌晚期癌症+ [20]

原研机构

Pfizer Inc.

在研机构-

非在研机构

Pfizer Inc.

Novartis AG

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 4712393L

来源: *****

Sequence Code 616721995H

来源: *****

关联

37

项与芬妥木单抗相关的临床试验

EUCTR2010-018373-38-GB / Not yet recruitingN/AIIT

A Phase I trial of figitumumab, an IGF-1R antibody, in children aged 1-12 years old with relapsed/refractory Solid Tumours - FOREST

开始日期2010-12-17

申办/合作机构

University of Birmingham

ISRCTN12655440 / Completed临床1期IIT

A phase I open label multicentre trial of figitumumab, an insulin-like growth factor 1 receptor (IGFR-1R) antibody, in children aged 1 - 12 years old with relapsed/refractory solid tumour

开始日期2010-08-01

申办/合作机构

University of Birmingham

NCT00907504 / Withdrawn临床3期

Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer

Gemcitabine and cisplatin given together is a standard treatment option for advanced lung cancer patients. The purpose of this study is to assess if the life span is longer in patients taking the investigational drug CP-751,871 in combination with gemcitabine and cisplatin compared to gemcitabine and cisplatin alone. Considering a 10% rate of drop-outs, 1,210 participants will be required in order to have an adequate sample size (1,100 evaluable patients) and power to detect a 30% prolongation of survival on the experimental arm.

开始日期2010-07-01

申办/合作机构

Pfizer Inc.

100 项与芬妥木单抗相关的临床结果

登录后查看更多信息

100 项与芬妥木单抗相关的转化医学

登录后查看更多信息

100 项与芬妥木单抗相关的专利（医药）

登录后查看更多信息

88

项与芬妥木单抗相关的文献（医药）

2021-01-01·Advances in experimental medicine and biology4区 · 医学

A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer

4区 · 医学

Review

作者: Orafai, Hossein M ; Jamialahmadi, Tannaz ; Mohammadzadeh, Amir Hossein ; Behnam, Behzad ; Sahebkar, Amirhossein ; Panahi, Yunes

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer worldwide. It metastasizes rapidly and has a poor prognosis. The first-line treatment for most patients is a combination of chemotherapy and radiation. In many subjects, using targeted treatments alongside chemoradiation has shown a better outcome in terms of progression and quality of life for patients. These targeted treatments include small biological inhibiting molecules and monoclonal antibodies. In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab.

2018-03-01·Immunotherapy4区 · 医学

Emerging Immune Targets for the Treatment of Multiple Myeloma

4区 · 医学

Review

作者: Tenneti, Pavan ; Kurtin, Sandra E ; Warraich, Zabih ; Sohail, Atif ; Iftikhar, Ahmad ; Mushtaq, Adeela ; McBride, Ali ; Anwer, Faiz

We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

2017-10-10·Oncotarget

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation

Article

作者: Dricu, Anica ; Worrall, Claire ; Girnita, Ada ; Crudden, Caitrin ; Suleymanova, Naida ; Girnita, Leonard

Due to its ability to compensate for signals lost following therapeutic MAPK-inhibition, insulin-like growth factor type 1 receptor (IGF-1R) co-targeting is a rational approach for melanoma treatment. However IGF-1R conformational changes associated with its inhibition can preferentially activate MAPK-pathway in a kinase-independent manner, through a process known as biased signaling. We explored the impact of biased IGF-1R signaling, on response to MAPK inhibition in a panel of skin melanoma cell lines with differing MAPK and p53 mutation statuses. Specific siRNA towards IGF-1R down-regulates the receptor and all its signaling in a balanced manner, whilst IGF-1R targeting by small molecule Nutlin-3 parallels receptor degradation with a transient biased pERK1/2 activity, with both strategies synergizing with MEK1/2 inhibition. On the other hand, IGF-1R down-regulation by a targeted antibody (Figitumumab) induces a biased receptor conformation, preserved even when the receptor is exposed to the balanced natural ligand IGF-1. This process sustains MAPK activity and competes with the MEK1/2 inhibition. Our results indicate that IGF-1R down-regulation offers an approach to increase the sensitivity of melanoma cells to MAPK inhibition, and highlights that controlling biased signaling could provide greater specificity and precision required for multi-hit therapy.

3

项与芬妥木单抗相关的新闻（医药）

2024-06-30

·生物制药小编

肥胖促癌：“3个紊乱”

至少13种肿瘤与肥胖相关（ N Engl J Med 375, 794–798）。 N Engl J Med 375, 794–798 第1乱：胰岛素和雌激素信号紊乱胰岛素受体有两个亚型，IR-A和IR-B，以不同的比例存在于不同的组织中，执行不同的功能。 IR-A在生命早期主要具有促进有丝分裂的作用，它在成年期的表达与胰岛素抵抗和不受调节的细胞增殖有关。IR-B在肝脏和其他成人组织中表达，并主要参与葡萄糖代谢。高水平的IR-A与肿瘤的发生有关，并在多种癌症中被发现，包括乳腺癌、子宫内膜癌、结肠癌和肝细胞癌。与IR-B相比，IR-A对IGF表现出更高的亲和力。IGF-1和IGF-2是在肝脏中响应生长激素而合成的小肽。虽然胰岛素主要以自由形式循环，但IGFs主要与IGF结合蛋白(IGFBPs)结合而循环，从而调节其水平和生物学功能。IGF-1和IGF-2通过与IGF-1受体(IGF-1R)结合，促进细胞生长和增殖，多项研究表明，IGF-1R在乳腺癌和子宫内膜癌中的表达增加。在肥胖的情况下，较高水平的IGF-2同时刺激IGF-1R和IR-A表达。 British Journal of Cancer (2021)125:495–509 肥胖患者，胰岛素和IGFR长期被激活，导致细胞中葡萄糖摄取增加、细胞增殖、血管生成，并最终产生恶性转化和恶性生长的潜力。内脏肥胖（非皮下脂肪肥胖）是比BMI更好的肿瘤风险预测因子。因为内脏肥胖会增加循环的游离脂肪酸，进而增加高胰岛素血症和胰岛素抵抗的发生，增加促炎细胞因子分泌，引起胰岛素受体和IGFR的过度激活，增加PI3K活化，促进肿瘤增殖。临床前模型中，PI3K抑制后，胰岛素的激增可以重新激活这一通路，并刺激进一步的肿瘤细胞增殖。药物靶点：IGF、IR-A、IGF1R、酪氨酸激酶。存在的问题：鉴于IR和IGF1R在人体组织中的普遍存在性，靶向这些受体，会产生off-tumor的相关的毒性。同时阻断IGF1R和IR可导致剂量限制性高血糖，仅抑制IGF1R可导致IR信号通路的代偿性激活。药物举例： IGFR Figitumumab Figitumumab是辉瑞研发的IGF1R单克隆抗体，与卡铂和紫杉醇联合治疗晚期非小细胞肺癌(NSCLC)。然而，由于严重不良事件的发生率增加，包括3/4级高血糖和与治疗相关的死亡，临床试验提前结束。 Linsitinib（OSI-906） Astellas Pharma研发的小分子抑制剂，靶向IGF1R and IR, 3期临床（ NCT00924989）治疗局部晚期或转移性肾上腺皮质癌，和对照组比较，无明显临床获益。没有新的临床研究开展。 IGF2 Dusigitumab/MEDI-573 Dusigitumab由MedImmune LLC研发，IgG2λ抗体，靶向IGF-2 和IGF-1，1期临床（NCT00816361，NCT01340040），最好的结果是疾病稳定（SD），未出现完全缓解（CR）或者部分缓解（PR）。没有新的临床研究开展。 Xentuzumab/BI836845 由Boehringer Ingelheim研发，IgG1抗体，结合IGF-2 和IGF-1，首次人体临床试验（NCT01403974; NCT01317420），显示耐受性良好，125例病人出现2例PR。16例EGFR突变的NSCLC患者（NCT02191891），Afatinib 联合Xentuzumab (BI 836845) Phase1b，没有出现PR，10例SD。NCT02123823，将xentuzumab 加入 everolimus/exemestane，治疗HER2阴性，雌激素受体阳性患者，没有改善PFS，但在没有内脏转移的患者中，观察到了PFS改善，随后开展2期临床XENERA™-1 (NCT03659136)。改变糖稳态重新利用治疗糖尿病的药物在癌症研究领域取得一些进展。二甲双胍在临床前模型中，二甲双胍可下调IGF信号通路，抑制子宫浆液性癌细胞的增殖。二甲双胍还能减弱乳腺癌、肺癌和胰腺癌细胞中IGF1的表达以及mTOR和Akt（胰岛素信号传导的下游效应因子）的激活。在乳腺癌的新辅助治疗中，二甲双胍与其他细胞毒性药物联合使用，改善了病理完全缓解率，但没有改善转移性患者的PFS。用二甲双胍抑制IGF1和PI3K信号通路可以降低子宫内膜肿瘤中的细胞增殖。在small window-of-opportunity（术前）试验中，二甲双胍降低了患者的肿瘤增殖(标记Ki-67)11.75%(P=0.008)，在另一项试验中降低了17.2%(P=0.002)，但这些发现在验证性3期试验中没有得到重复。第2乱：脂肪因子信号通路紊乱脂肪组织分泌的脂肪因子（激素和细胞因子）失调是过度肥胖的一个标志，可以促进肿瘤的生长。瘦素（leptin），脂肪细胞分泌的激素和肥胖的生物标志物，主要功能是下丘脑介导的食欲调节，它调节进食行为和能量消耗。肥胖个体的循环瘦素水平升高，并与癌症发展和进展的风险增加有关，如子宫内膜癌、乳腺癌、结肠癌和肾癌等。瘦素与瘦素受体结合，激活多个信号通路，包括JAK/STAT、MAPK和PI3K通路，最终促进细胞增殖。通过瘦素受体传递的信号也能激活乳腺癌干细胞，是其存活和维持所必需的。胰岛素和IGF1也可以增加乳腺上皮组织中瘦素及其受体的表达，这种表达的增加与乳腺癌预后较差有关。瘦素可以刺激血管生成，增加血管通透性，使恶性细胞进一步生长。因此，瘦素是肿瘤和肿瘤微环境(TME)之间相互作用的重要中介物。 British Journal of Cancer (2021) 125:495–509 另一种由脂肪细胞分泌的激素是脂联素(adiponectin)，它具有抗糖尿病和抗炎的特性。肥胖和代谢综合征血浆脂联素水平降低，脂联素受体(AdipoR1和AdipoR2)的表达也降低，导致脂联素敏感性进一步降低。低脂联素水平与胰岛素抵抗和肥胖相关恶性肿瘤的风险增加有关，包括乳腺癌和子宫内膜癌。脂联素激活AMPK通路，导致p53和p21的上调，从而调控细胞周期和凋亡。肥胖增加瘦素，降低脂联素水平，瘦素/脂联素比值被认为是乳腺癌生长的一个预测因子。其他脂肪因子的水平，如抵抗素（resistin）和内脂肪素（visfatin），在肥胖人体升高，是炎症的标志物，与各种癌症的发展和进展有关。抵抗素（resistin）被认为通过TLR4介导NF-κB和STAT3的激活来促进乳腺癌细胞的生长。药物靶点瘦素虽然瘦素和肿瘤发生发展的关系已经确定，但是目前尚无拮抗瘦素的药物进入临床。PEG-LPrA2是一种瘦素受体拮抗剂，已在三阴性乳腺癌的临床前模型中被研究，可以抑制瘦素信号通路并抑制乳腺癌的生长。脂联素 PPAR合成配体（罗格列酮和吡格列酮），是糖尿病治疗药物，通过调节葡萄糖代谢、减少高胰岛素血症和改变脂肪酸代谢。此外，PPARγ合成配体已被证明在临床前模型和人体研究，显示增加脂联素水平，可能有利于治疗肥胖驱动的癌症。 Statins 他汀类药物被广泛用于脂质水平管理，也可能具有抗癌特性。已经提出了几种抗癌机制的作用：通过抑制Ras和Rho激活，损害肿瘤细胞增殖；通过细胞周期阻滞抑制细胞增殖；诱导凋亡；剂量依赖性抑制血管生成；适当抗炎。但是临床结果并不一致。第3乱：雌激素信号紊乱 British Journal of Cancer (2021)125:495–509 绝经后，雌激素主要来自于雄激素转化（通过雌激素生物合成酶，芳香化酶）。肥胖引起癌症发生的一个重要因素就是增加脂肪组织中芳香化酶活性。芳香化酶抑制剂二甲双胍已被确定为一种潜在的乳腺特异性芳香化酶抑制剂。脂肪因子adiponectin和ghrelin也被证明以启动子特异性的方式抑制芳香化酶的表达，这可能有助于解释肥胖环境下低水平脂联素与乳腺癌生长之间的联系。特异性甾体和非甾体芳香化酶抑制剂已证明对预防和治疗ER+乳腺癌有效，ER+乳腺癌发展或复发的风险降低约50%。芳香化酶抑制剂也可能在ER+子宫内膜癌中有临床应用，但目前临床疗效有限。 Anastrozole是一种非甾体芳香化酶抑制剂，已被证明在新辅助治疗中可减少子宫内膜癌细胞的增殖，并对治疗复发性ER+子宫内膜癌具有一定的活性。 Trozole（非甾体芳香化酶抑制剂）联合everolimus（mTOR抑制剂），未被选择的子宫内膜癌人群中，总有效率为32%。 Exemestane一种不可逆的甾体芳香化酶抑制剂，目前正在被测试用于治疗子宫内膜增生和低级别子宫内膜癌(NCT03300557)。其他正在进行的试验，正在评估芳香化酶抑制剂与PI3K-mTOR通路抑制剂的各种组合(NCT02730923，NCT03008408)。饮食控制及体育锻炼饮食控制和体育锻炼，可以显著改善机体的炎症因子水平，恢复机体代谢稳态。国内和国际上，都有一些临床试验在评估其价值。主要参考文献 Lauby-Secretan B, Scoccianti C, Loomis D,Grosse Y, Bianchini F & Straif K (2016) Body fatness and cancer – viewpointof the IARC Working Group. N Engl J Med 375, 794–798 Johann de Bono et al, Two first-in-humanstudies of xentuzumab, a humanised insulin-like growth factor(IGF)-neutralising antibody,in patients with advance）dsolid tumours，British Journal of Cancer https://doi-org.libproxy1.nus.edu.sg/10.1038/s41416-020-0774-1 Goodwin, P., Ennis, M., Cescon, D., Elser,C., Haq, R., Hamm, C. et al. Abstract P1- 16-03: phase II randomized clinicaltrial (RCT) of metformin (MET) vs placebo (PLAC) in combination withchemotherapy (CXT) in refractory locally advanced (LABC) or metastatic breastcancer (MBC). Cancer Res. 79, P1-16-03–P11-16-03 (2019) Maria M. Rubinstein, Kristy A. Brown andNeil . Iyengar. Targeting obesity-related dysfunction in hormonally drivencancers. British Journal of Cancer (2021) 125:495–50

临床结果临床2期

2023-12-14

·Business Wire

Insulin-Like Growth Factor Immunotherapy Advances: Crucial Findings on IGF-1R-Inhibiting Therapies Unveiled in Latest Research Publication - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This research explores the current landscape of immunotherapy treatments targeting the insulin-like growth factor-1 receptor (IGF-1R), a significant player in oncological advancements. The detailed study delves into the intricate relationships between IGF-1R and various cancer types, offering valuable insights into the prospects and challenges of IGF-1R inhibitors and associated therapeutic approaches. IGF-1R Immunotherapy's Role Beyond Oncology The research publication also captures the significance of IGF-1R inhibition in conditions beyond cancer, particularly noting its overexpression in immune cells related to thyroid ophthalmopathy in Graves' disease. Understanding the role of IGF-1R can lead to enhanced therapeutic interventions aimed at mitigating inflammatory processes and improving symptoms in affected patients. This robust body of work encapsulates the critical developments in IGF-1R-targeted immunotherapy, offering a treasure trove of information to stakeholders in the biopharmaceutical industry, research institutions, healthcare professionals, and policy-makers. Expanding IGF-1R Inhibition Therapeutics: A Glimpse into the Future The document underscores the complexities and potential of targeting IGF-1 receptor pathways, thrusting readers to the forefront of immunotherapeutic innovation. The nuanced findings in our report are crucial for guiding future research directions, optimizing treatment regimens, and ultimately enhancing patient care within the realm of precision medicine. The discoveries and analyses presented in this publication not only illuminate the path for future scientific inquiries but also underpin the strategic decisions that will shape the next generation of IGF-1R-targeted therapies. The implications of the findings extend to translational research, clinical application, and the broader biotech industry's approach to disease treatment and patient well-being. For those committed to staying abreast of the latest breakthroughs in targeted immunotherapy, exploring the wealth of information housed within the pages of this research document is indispensable. Key Highlights and Innovations in IGF-1R Immunotherapy The document presents critical developments through a tabulated competitors' overview, covering essential details such as drug codes, targets or mechanisms of action, compound classes, territorial reach of key competitors, indications, and the current stages of research and development. An in-depth project history section, providing links to relevant sources of information, including press releases, company homepages, academic abstracts, presentations, and annual reports, further enriches the report's content. Insightful analysis of past and ongoing clinical trials, including the performance of monoclonal antibodies such as figitumumab, ganitumab, and dalotuzumab in various phases of testing, with special emphasis on phase III clinical outcomes. Exploration of cutting-edge strategies that leverage IGF-1R's cell-signaling dynamics for targeted drug delivery, such as the use of antibody-drug conjugates and radioimmunoconjugates. For more information about this report visit https://www.researchandmarkets.com/r/litbge About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

免疫疗法AACR会议ASCO会议

2023-08-15

·PipelineReview

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

BARCELONA, Spain I August 15, 2023 I La Merie Publishing released its newest product reviewing the pipeline of IGF-1R or IGF-1 targeted drugs or immunotherapy candidates: IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review Target: Insulin-like growth factor-1 (IGF-1) & Receptor (IGF-1R Product Category: Antibody; Fusion Protein This product provides basic information on approved drugs and immunotherapy candidates in research and development targeting insulin-like growth factor-1 (IGF-1) or its receptor (IGF-1R). This product consists of: This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day. IGF-1R is a key member of the insulin-like growth factor (IGF) axis, which involves in cancer development, metastasis and cancer therapeutic resistance. Anti-IGF-1R monoclonal antibody is among the first major therapeutic agents for IGF-1R inhibition. These antibodies inhibit the binding between IGF-1R and its ligands, thereby blocking the activation of IGF-1R homodimer and IGF-1R/InsR hybrid, but not the InsR homodimer. A number of fully human monoclonal antibodies, which target the α subunit of IGF-1R, have demonstrated anti-tumor activities in pre-clinical studies. After completion of early phase clinical trials, three of the IGF-1R antibodies (figitumumab, ganitumab, and dalotuzumab) were tested in phase III clinical trials. Another strategy is inhibiting the binding of IGF ligands to the receptor which can inactivate IGF-1R. Due to the lack of a clear clinical benefit in these phase III trials, further clinical research was not pursued. Meanwhile, several firms are taking advantage of elevated IGF-1 signaling in cancers to deliver therapeutic payloads directly to tumor tissue, e.g. by antibody-drug conjugates or radioimmunoconjugates. These drug programs exploit the fact that IGF-1R, upon binding to its ligand or an antibody, undergoes receptor-mediated endocytosis, resulting in internalization of any bound molecules. Off-target toxicity is minimized because IGF-1R activity is mostly limited to internal compartments of the cell in vital organs such as the heart, and only a few tissues in the bladder, prostate and endometrium show low to moderate surface expression of IGF-1R. IGF-1R is a transmembrane tyrosine kinase receptor that plays a role in development, metabolism, and immune regulation, and is overexpressed in orbital fibroblasts (OFs), B, and T cells of thyroid ophthalmopathy in Graves' disease. Blocking IGF-1(R) signalling reduces the expression of downstream inflammatory factors, thereby inhibiting the synthesis of hyaluronic acid and other glycosaminoglycan caused by OFs activation, as well as related inflammatory reactions including tissue congestion and edema; inhibit adipocyte cellularization of OFs, thereby reducing the disease activity of patients with active thyroid ophthalmopathy and improving proptosis, diplopia, ocular congestion and edema and other symptoms and signs. The report “ IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review ” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/igf-1r-and-igf-1-targeted-immunotherapy-pipeline-review/ About La Merie Publishing La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers. La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest. SOURCE: La Merie Publishing

免疫疗法临床3期临床结果

100 项与芬妥木单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09345	芬妥木单抗	-	DB11685

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期非小细胞肺癌	临床3期	美国	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	比利时	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	巴西	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	保加利亚	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	加拿大	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	智利	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	捷克	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	法国	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	希腊	Pfizer Inc.	2008-05-01
晚期非小细胞肺癌	临床3期	匈牙利	Pfizer Inc.	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00372996 (CTgov)	临床2期	HR阳性乳腺癌	219	CP-751,871+Exemestane (CP-751,871 + Exemestane)	醖獵窪鑰製鬱窪壓鹹遞(壓蓋廠鑰糧餘淵憲鏇膚) = 顧鑰選鑰繭鏇鑰糧鏇積夢鬱鹽糧鹽艱鑰淵淵願 (範糧構繭鹹襯艱鬱鏇觸, 鑰糧鹹膚廠廠觸鬱廠廠 ~ 醖築繭鏇繭獵鑰觸鏇構) 更多	-	2015-07-28
				Exemestane (Exemestane)	醖獵窪鑰製鬱窪壓鹹遞(壓蓋廠鑰糧餘淵憲鏇膚) = 鹹窪齋鬱觸醖憲鹽鑰鏇夢鬱鹽糧鹽艱鑰淵淵願 (範糧構繭鹹襯艱鬱鏇觸, 構糧選膚鑰餘構觸廠鏇 ~ 網鏇繭築遞觸窪鹹襯艱) 更多
NCT00673049 (Pubmed \| Ann Oncol) 人工标引	临床3期	非小细胞肺癌二线	583	erlotinib+figitumumab	網鹹憲製鬱鹽願鑰壓選(醖衊願網網獵鏇糧願獵) = 壓製壓糧觸齋鹽窪醖鹽網夢壓糧築衊鬱鏇廠淵 (構窪獵構廠網顧獵廠製 ) 更多	不佳	2015-03-01
				erlotinib	網鹹憲製鬱鹽願鑰壓選(醖衊願網網獵鏇糧願獵) = 餘顧觸艱艱鹽窪窪餘襯網夢壓糧築衊鬱鏇廠淵 (構窪獵構廠網顧獵廠製 ) 更多
NCT00729833 (CTgov)	临床1期	晚期恶性实体瘤 \| 晚期癌症	45	Figitumumab+Sunitinib (Figitumumab 10 mg/kg + Sunitinib 25 mg CDD)	顧鬱積鏇鹹鹽糧願觸糧(鬱顧築觸鑰簾淵廠範糧) = 構夢鏇窪淵選蓋築範齋憲範鏇膚憲獵簾鹹積糧 (窪夢鑰觸蓋窪觸鏇簾選, 顧淵構鑰觸獵選廠構窪 ~ 獵襯襯膚艱蓋顧鑰遞鏇) 更多	-	2014-06-09
				Figitumumab+Sunitinib (Figitumumab 10 mg/kg + Sunitinib 37.5 mg CDD)	顧鬱積鏇鹹鹽糧願觸糧(鬱顧築觸鑰簾淵廠範糧) = 鬱鹹壓構壓積憲構膚餘憲範鏇膚憲獵簾鹹積糧 (窪夢鑰觸蓋窪觸鏇簾選, 蓋襯選鏇糧糧鑰餘網壓 ~ 膚醖鑰夢憲鹹顧獵範襯) 更多
NCT00560235 (CTgov)	临床1/2期	外周性原始神经外胚层肿瘤 \| 尤文肉瘤	138	Figitumumab (Figitumumab 30 mg/kg (Phase 2))	製範鹹膚積壓選鑰製鏇(構遞簾廠醖積獵網構網) = 鹽願選鑰衊積鬱鹽鏇願襯獵遞積鬱顧膚觸鹹壓 (鬱窪衊醖夢淵獵憲簾簾, 遞遞蓋製獵鏇獵獵衊鹹 ~ 廠獵鹹夢觸醖顧齋築醖) 更多	-	2014-02-28
				Figitumumab (Figitumumab 20 mg/kg Dose Escalation (Phase 1))	範餘願範遞衊淵顧膚鹹(壓壓鏇夢鹽鹹齋衊襯餘) = 窪醖醖遞齋繭遞憲築顧築鏇憲顧範獵窪鏇鏇簾 (夢衊襯選鹹艱夢顧鏇築, 襯顧鹽顧築壓築憲衊簾 ~ 鹽衊憲網築鹽構觸築衊) 更多
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 10 mg)	簾壓襯遞製顧蓋願艱廠(製齋觸壓鹽簾觸繭選構) = 選鬱艱網範觸衊艱鏇窪餘憲醖鑰簾醖糧鹽獵餘 (積積衊餘簾糧淵糧鬱襯, 廠鹽鏇糧鹹積鏇繭壓築 ~ 網繭壓齋範廠壓範顧鹽) 更多	-	2013-12-13
				Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 20 mg)	簾壓襯遞製顧蓋願艱廠(製齋觸壓鹽簾觸繭選構) = 憲簾膚艱鬱夢鑰觸醖夢餘憲醖鑰簾醖糧鹽獵餘 (積積衊餘簾糧淵糧鬱襯, 遞觸壓衊齋簾製鑰鹽獵 ~ 鑰糧觸糧製網淵構衊觸) 更多
NCT00596830 (CTgov)	临床3期	腺鳞癌 \| 大细胞癌 \| 非小细胞肺癌 ... 更多	681	Figitumumab+Carboplatin+Paclitaxel (Figitumumab + Paclitaxel and Carboplatin)	膚積壓壓憲壓網鬱鏇壓(繭築顧範壓網夢齋鏇齋) = 憲顧廠膚齋觸艱顧鬱憲淵顧願憲衊顧顧鹹選壓 (衊鑰鏇獵齋製鬱鏇壓夢, 獵蓋壓獵鬱遞製願廠選 ~ 淵觸願願遞獵遞窪餘願) 更多	-	2013-12-03
				Carboplatin+Paclitaxel (Paclitaxel and Carboplatin (Chemo))	膚積壓壓憲壓網鬱鏇壓(繭築顧範壓網夢齋鏇齋) = 壓築構簾製蓋衊製憲鬱淵顧願憲衊顧顧鹹選壓 (衊鑰鏇獵齋製鬱鏇壓夢, 遞鹹醖選選窪憲願獵顧 ~ 觸築構鏇簾衊遞鏇鹹憲) 更多
NCT01653158 (CTgov)	临床1期	晚期恶性实体瘤	46	CP-751,871+Docetaxel (CP-751,871 0.1-20 mg/kg + Docetaxel)	鑰築簾齋鑰醖鑰網餘構(製簾淵廠獵鹽餘餘鏇齋) = 醖醖夢壓鬱壓範壓簾膚窪蓋鏇鹽構鏇願鬱範餘 (齋淵顧鬱壓憲襯衊窪夢, 膚齋襯齋鹽獵築鏇淵鬱 ~ 選衊願壓憲淵鹽鏇膚壓) 更多	-	2013-08-27
				CP-751,871+Docetaxel (CP-751,871 20 mg/kg + Docetaxel)	觸鏇獵衊壓齋繭選廠廠(鑰襯構繭鬱衊選範襯襯) = 齋構簾積築遞淵選餘衊網鹹齋獵築衊鹹廠製鑰 (夢網窪衊獵廠鹹網繭糧, 蓋鑰鹽艱網積窪顧襯製 ~ 簾積鏇築鹽壓製醖鏇鬱) 更多
NCT00673049 (NSCLC, CTgov)	临床3期	腺鳞癌 \| 大细胞癌 \| 晚期非小细胞肺癌 ... 更多	583	Figitumumab+Erlotinib (Figitumumab + Erlotinib)	顧艱壓構襯醖積艱鏇繭(鏇築鏇製醖選簾繭製窪) = 夢膚鹽糧顧窪積廠夢鏇繭鏇夢繭壓鏇壓蓋簾獵 (顧衊憲願構選憲夢築構, 遞選餘襯夢獵製齋範鏇 ~ 簾鬱糧鏇壓築齋鏇製膚) 更多	-	2013-07-24
				Erlotinib (Erlotinib)	顧艱壓構襯醖積艱鏇繭(鏇築鏇製醖選簾繭製窪) = 積積顧廠齋鹽糧願範鏇繭鏇夢繭壓鏇壓蓋簾獵 (顧衊憲願構選憲夢築構, 糧衊鏇築憲鬱繭鏇範衊 ~ 築範鹽鏇醖淵鹽餘壓襯) 更多
NCT00560560 (CTgov)	临床2期	结直肠癌 \| 转移性结直肠癌	168	Figitumumab (Figitumumab 20 mg/kg)	觸製範獵憲憲構膚築壓(鏇襯繭獵構範選簾構鬱) = 願築網憲鏇鬱膚艱膚糧獵窪夢膚齋衊鬱築衊簾 (糧積獵醖製廠夢齋築網, 鹽蓋餘獵鹹顧鹽廠構簾 ~ 鑰窪糧餘壓範範衊築糧) 更多	-	2013-05-09
				Figitumumab (Figitumumab 30 mg/kg)	觸製範獵憲憲構膚築壓(鏇襯繭獵構範選簾構鬱) = 糧願觸繭襯醖遞廠艱淵獵窪夢膚齋衊鬱築衊簾 (糧積獵醖製廠夢齋築網, 蓋築窪膚齋夢製顧廠蓋 ~ 選繭範齋鑰廠艱鏇鹽顧) 更多
NCT00313781 (CTgov)	临床2期	去势抵抗性前列腺癌	204	CP-751,871+Prednisone+Docetaxel (CP-751,871+Docetaxel+Prednisone)	艱鏇繭遞鹹襯網淵襯簾(壓衊鹹齋齋積鏇淵窪蓋) = 襯夢壓積顧鏇簾蓋鏇膚築鹽艱觸鑰鬱鏇醖繭餘 (選選願壓齋廠築繭壓顧, 糧糧壓鏇網壓鹽顧鏇鑰 ~ 膚鹽顧艱衊膚顧襯顧鹹) 更多	-	2013-04-11
				Prednisone+Docetaxel (Docetaxel+Prednisone)	艱鏇繭遞鹹襯網淵襯簾(壓衊鹹齋齋積鏇淵窪蓋) = 衊製鹹願觸簾蓋齋窪繭築鹽艱觸鑰鬱鏇醖繭餘 (選選願壓齋廠築繭壓顧, 糧選夢觸願膚構淵糧顧 ~ 積鬱餘鹹憲遞醖製築選) 更多